XML 15 R5.htm IDEA: XBRL DOCUMENT v3.19.2
Condensed Consolidated Statements of Stockholders' Equity - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid-in Capital
Accumulated Deficit
Accumulated Other Comprehensive Income (Loss)
Non- Controlling Interest
Beginning Balances (in shares) at Dec. 31, 2017   85,598        
Beginning Balances at Dec. 31, 2017 $ 187,900 $ 856 $ 682,809 $ (495,479) $ (286)  
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Cumulative-effect adjustment of ASC | Topic 606 1,117     1,117    
Issuance of common stock upon exercise of stock options and in connection with restricted stock units, net of tax (in shares)   1,443        
Issuance of common stock upon exercise of stock options and in connection with restricted stock units, net of tax 10,584 $ 14 10,570      
Stock-based compensation 3,050   3,050      
Net unrealized gain (loss) on marketable securities (99)       (99)  
Net loss (20,187)     (20,187)    
Ending Balances (in shares) at Mar. 31, 2018   87,041        
Ending Balances at Mar. 31, 2018 182,365 $ 870 696,429 (514,549) (385)  
Beginning Balances (in shares) at Dec. 31, 2017   85,598        
Beginning Balances at Dec. 31, 2017 187,900 $ 856 682,809 (495,479) (286)  
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net unrealized gain (loss) on marketable securities 131          
Net loss (36,827)          
Ending Balances (in shares) at Jun. 30, 2018   101,624        
Ending Balances at Jun. 30, 2018 387,867 $ 1,016 918,197 (531,189) (157)  
Beginning Balances (in shares) at Mar. 31, 2018   87,041        
Beginning Balances at Mar. 31, 2018 182,365 $ 870 696,429 (514,549) (385)  
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Issuance of common stock upon exercise of stock options and in connection with restricted stock units, net of tax (in shares)   263        
Issuance of common stock upon exercise of stock options and in connection with restricted stock units, net of tax 1,954 $ 2 1,952      
Issuance of common stock under employee stock purchase plan (in shares)   163        
Issuance of common stock under employee stock purchase plan 690 $ 2 688      
Issuance of common stock under public offering, net of issuance costs (in shares)   14,157        
Issuance of common stock under public offering, net of issuance costs 215,756 $ 142 215,614      
Stock-based compensation 3,514   3,514      
Foreign currency translation adjustment (2)       (2)  
Net unrealized gain (loss) on marketable securities 230       230  
Net loss (16,640)     (16,640)    
Ending Balances (in shares) at Jun. 30, 2018   101,624        
Ending Balances at Jun. 30, 2018 387,867 $ 1,016 918,197 (531,189) (157)  
Beginning Balances (in shares) at Dec. 31, 2018   102,188        
Beginning Balances at Dec. 31, 2018 367,257 $ 1,022 929,632 (562,696) (1,440) $ 739
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Cumulative-effect adjustment of ASC | Topic 842 897     897    
Issuance of common stock upon exercise of stock options and in connection with restricted stock units, net of tax (in shares)   141        
Issuance of common stock upon exercise of stock options and in connection with restricted stock units, net of tax 216 $ 1 215      
Issuance costs related to public offering and TxCell Acquisition (258)   (258)      
Stock-based compensation 4,523   4,523      
Foreign currency translation adjustment (1,504)       (1,504)  
Net unrealized gain (loss) on marketable securities 253       253  
Net loss (42,203)     (42,150)   (53)
Ending Balances (in shares) at Mar. 31, 2019   102,329        
Ending Balances at Mar. 31, 2019 329,181 $ 1,023 934,112 (603,949) (2,691) 686
Beginning Balances (in shares) at Dec. 31, 2018   102,188        
Beginning Balances at Dec. 31, 2018 367,257 $ 1,022 929,632 (562,696) (1,440) 739
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net unrealized gain (loss) on marketable securities 737          
Net loss (72,559)          
Ending Balances (in shares) at Jun. 30, 2019   115,603        
Ending Balances at Jun. 30, 2019 445,748 $ 1,156 1,078,976 (634,233) (765) 614
Beginning Balances (in shares) at Mar. 31, 2019   102,329        
Beginning Balances at Mar. 31, 2019 329,181 $ 1,023 934,112 (603,949) (2,691) 686
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Issuance of common stock upon exercise of stock options and in connection with restricted stock units, net of tax (in shares)   492        
Issuance of common stock upon exercise of stock options and in connection with restricted stock units, net of tax 2,444 $ 5 2,439      
Issuance of common stock under employee stock purchase plan (in shares)   132        
Issuance of common stock under employee stock purchase plan 1,138 $ 1 1,137      
Issuance of common stock under public offering, net of issuance costs (in shares)   12,650        
Issuance of common stock under public offering, net of issuance costs 136,566 $ 127 136,439      
Issuance costs related to public offering and TxCell Acquisition (18)   (18)      
Stock-based compensation 4,867   4,867      
Foreign currency translation adjustment 1,442       1,442  
Net unrealized gain (loss) on marketable securities 484       484  
Net loss (30,356)     (30,284)   (72)
Ending Balances (in shares) at Jun. 30, 2019   115,603        
Ending Balances at Jun. 30, 2019 $ 445,748 $ 1,156 $ 1,078,976 $ (634,233) $ (765) $ 614